Table 3.
Associationsa between sociodemographic and clinical characteristics and sexual function among women with severe obesity prior to bariatric surgery.
| Lower frequency of sexual desire |
Lower frequency of sexual activity |
Higher degree physical health limits sexual activity |
Lower satisfaction with sex life |
Lower IWQOL-Lite sexual life score |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | (95%CI) | P | OR | (95%CI) | P | OR | (95%CI) | P | OR | (95%CI) | P | β | (95%CI) | P | |
| Age, per 10 year | 1.56 | (1.31–1.86) | <.0001 | 1.60 | (1.35–1.90) | <.0001 | 1.11 | (0.93–1.33) | 0.23 | 1.00 | (0.84–1.19) | 0.98 | 1.06 | (−0.89–3.02) | 0.29 |
| White race (Ref.=black/other race) | 1.61 | (1.09–2.36) | 0.02 | 1.53 | (1.04–2.25) | 0.03 | 1.19 | (0.80–1.76) | 0.39 | 1.58 | (1.07–2.33) | 0.02 | 10.03 | (5.77–14.30) | <.0001 |
| Hispanic ethnicity (Ref.=No) | 0.69 | (0.36–1.32) | 0.26 | 1.22 | (0.64–2.32) | 0.55 | 1.00 | (0.53–1.92) | 0.99 | 0.79 | (0.42–1.50) | 0.48 | 3.90 | (−3.77–11.57) | 0.32 |
| Education (Ref.= College degree) | 0.001 | ||||||||||||||
| Some college | 1.22 | (0.92–1.63) | |||||||||||||
| High school degree or less | 1.92 | (1.36–2.71) | |||||||||||||
| Not married/living as married (Ref.=Yes) | 1.26 | (0.96–1.66) | 0.09 | 2.45 | (1.86–3.23) | <.0001 | 0.28 | (0.21–0.37) | <.0001 | 1.00 | (0.76–1.31) | 0.97 | 0.10 | (−2.98–3.19) | 0.95 |
| Alcohol use disorder symptoms (Ref.=Yes) | 1.98 | (1.18–3.32) | 0.01 | ||||||||||||
| BMI, per 5 kg/m2 | 0.94 | (0.86–1.03) | 0.16 | 1.06 | (0.97–1.16) | 0.19 | 1.14 | (1.04–1.25) | 0.004 | 0.94 | (0.86–1.03) | 0.19 | −0.29 | (−1.29–0.72) | 0.58 |
| Beck Depression Inventory score, per 5 points | 1.33 | (1.20–1.48) | <.0001 | 1.25 | (1.13–1.39) | <.0001 | 1.89 | (1.70–2.11) | <.0001 | 1.84 | (1.65–2.05) | <.0001 | 9.52 | (8.36–10.68) | <.0001 |
| Cardiovascular disease (Ref.=No) | 2.35 | (1.30–4.25) | 0.005 | 12.64 | (5.83–19.45) | 0.0003 | |||||||||
| Urinary incontinence (Ref.=No) | 1.68 | (1.29–2.19) | 0.0001 | 1.64 | (1.26–2.13) | 0.0002 | 7.90 | (4.95–10.84) | <.0001 | ||||||
| Menopausal (Ref.=No) | 1.49 | (0.96–2.30) | 0.07 | 1.69 | (1.09–2.62) | 0.02 | 1.02 | (0.66–1.59) | 0.92 | 0.99 | (0.64–1.54) | 0.98 | −4.15 | (−9.05–0.75) | 0.10 |
| Prior live or still birth (Ref=No) | −3.68 | (−6.89–−0.48) | 0.02 | ||||||||||||
| Antidepressant medications that may decrease sexual function b (Ref.=No) | 1.61 | (1.22–2.12) | 0.001 | 1.60 | (1.21–2.12) | 0.001 | 1.42 | (1.07–1.87) | 0.01 | 1.30 | (0.98–1.72) | 0.07 | 4.54 | (1.42–7.66) | 0.004 |
| Medications that may increase sexual function c (Ref.=No) | 0.87 | (0.53–1.42) | 0.57 | 1.05 | (0.64–1.73) | 0.85 | 0.72 | (0.44–1.19) | 0.20 | 1.64 | (1.26–2.13) | 0.19 | 1.31 | (−4.28–6.91) | 0.65 |
| Hormonal medications with unknown impact on sexual functiond | 2.02 | (1.21–3.37) | 0.01 | ||||||||||||
a
Adjusted odds ratios (OR)a from mixed effects ordinal logistic regression models or Beta coefficients from a generalized linear mixed model and 95% CI are reported. OR represent the odds of being in the next lower category
b
Antidepressant medications other than bupropion, trazodone, mirtazapine or nefazodone.
c
Phosphodiesterase type 5 inhibitors and bupropion.
d
Estrogens, progestins, and androgens, either alone or in combination.